Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Milestone Scientific (MLSS) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Milestone Scientific (MLSS) over the last 14 years, with Q3 2025 value amounting to $4556.0.

  • Milestone Scientific's Gains from Investment Securities rose 7556.84% to $4556.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $11952.0, marking a year-over-year increase of 1390.45%. This contributed to the annual value of $10136.0 for FY2024, which is 822.12% up from last year.
  • As of Q3 2025, Milestone Scientific's Gains from Investment Securities stood at $4556.0, which was up 7556.84% from $2278.0 recorded in Q1 2025.
  • Over the past 5 years, Milestone Scientific's Gains from Investment Securities peaked at $4556.0 during Q3 2025, and registered a low of $1883.0 during Q1 2021.
  • Its 5-year average for Gains from Investment Securities is $2418.2, with a median of $2211.5 in 2022.
  • As far as peak fluctuations go, Milestone Scientific's Gains from Investment Securities plummeted by 2830.54% in 2021, and later skyrocketed by 7556.84% in 2025.
  • Milestone Scientific's Gains from Investment Securities (Quarter) stood at $2869.0 in 2021, then decreased by 28.27% to $2058.0 in 2022, then surged by 39.94% to $2880.0 in 2023, then fell by 12.4% to $2523.0 in 2024, then soared by 80.58% to $4556.0 in 2025.
  • Its Gains from Investment Securities stands at $4556.0 for Q3 2025, versus $2278.0 for Q1 2025 and $2523.0 for Q4 2024.